How Long Does a Mitral Valve Repair Last?

A well-performed mitral valve repair typically lasts decades. In studies tracking patients for 20 years after surgery for degenerative mitral valve disease, about 90% remained free from reoperation, and roughly three-quarters had not experienced significant recurrent leakage.¹ Those numbers are reassuring, but they also hide a lot of variation. Which leaflet was prolapsing, how the surgeon fixed it, what caused the valve to leak in the first place, and even the hospital where the operation was performed all shift the odds in meaningful ways.

Posterior Leaflet Repairs Hold Up Best

The mitral valve has two leaflets, and the one involved in the leak matters more than most patients realize. Repairs for isolated posterior leaflet prolapse show the strongest track record: freedom from reoperation at 15 years exceeds 90%.² When the anterior leaflet is involved, or when both leaflets are prolapsing, that figure drops to roughly 70–85% over the same period.² The anterior leaflet is larger and more structurally complex, which makes it harder to repair in a way that stays durable over time.

Anterior leaflet prolapse also shows up consistently as an independent predictor of recurrent leakage in studies looking at why repairs fail. One analysis found that an isolated anterior leaflet lesion more than doubled the risk of recurrent regurgitation.³ This does not mean anterior leaflet repairs are unreliable, just that they require more technical skill and tend to carry somewhat lower long-term durability than posterior leaflet repairs.

The Underlying Cause Shapes the Outcome

Most discussions about mitral repair durability focus on degenerative disease, which is the most common reason for repair in high-income countries. Degenerative disease includes two broad categories: Barlow disease, where excessive tissue and redundancy create billowing leaflets, and fibroelastic deficiency, where the tissue is thinner and a single chord ruptures. A long-term comparison of the two found recurrence rates of about 2.9% per year for Barlow disease and 2.2% per year for fibroelastic deficiency, a gap that was not statistically significant.⁴ So while Barlow valves are technically more complex to repair, a skilled surgeon can achieve comparable long-term results with either type.

Functional mitral regurgitation is a different situation entirely. Here the valve leaflets themselves are structurally normal; the leak happens because the heart muscle has weakened or dilated, pulling the leaflets apart. A study comparing ischemic (caused by heart attacks) versus non-ischemic functional regurgitation found that roughly a quarter of patients in both groups had at least moderate recurrent leakage by 10 years, with reoperation rates around 3% for each.⁵ The recurrence rate is higher than with degenerative repairs because the underlying heart muscle problem can continue to worsen regardless of what happens to the valve.

Rheumatic mitral valve disease, which is far more common in lower-income countries, presents yet another durability profile. One study of rheumatic patients found that 10-year freedom from reoperation was about 97% after repair, similar to the 94% seen after mechanical valve replacement.⁶ This is encouraging, though rheumatic disease can progress and stiffen the valve over time, which means younger rheumatic patients face a higher lifetime chance of eventually needing another intervention.

How Surgical Technique Affects Longevity

Two broad approaches dominate mitral valve repair: leaflet resection, where the surgeon cuts out a section of the floppy tissue, and chordae replacement, where artificial cords made of expanded polytetrafluoroethylene (ePTFE, often called Gore-Tex) are placed to support the leaflet. Both techniques yield excellent freedom from reoperation at 10 to 15 years, generally in the range of 93–98%.⁷ However, there may be differences beneath those headline numbers. One study found that patients who received chordae replacement had a notably higher rate of recurrent mitral regurgitation at 15 years (about 33%) compared to those who underwent leaflet resection (about 12%), as well as a higher reoperation rate.⁸ This does not necessarily mean artificial chords are inferior across the board; many surgeons now use a “respect rather than resect” philosophy that combines artificial chords with edge-to-edge techniques, and long-term data on these newer hybrid approaches are still accumulating.

Nearly all modern repairs include an annuloplasty ring, a supportive band sutured around the valve opening to restore its normal shape and prevent future dilation. Skipping the ring is one of the clearest risk factors for failure.⁹ Whether that ring should be rigid or flexible has been debated for decades. In degenerative disease, one randomized trial comparing rigid and flexible rings found no significant difference in recurrence of significant regurgitation at eight years.¹⁰ A smaller study echoed this, showing comparable outcomes at five years.¹¹ In heart failure patients, however, the choice may matter more. One study found that a rigid, undersized ring dramatically reduced reoperation rates compared to a flexible ring in patients with poor heart function.¹²

What Predicts Failure

Certain signals, some measurable before surgery and some visible immediately after, strongly predict whether a repair will hold. Leaving the operating room with anything more than trivial residual leakage is one of the most powerful predictors. One study found that moderate regurgitation at discharge was associated with roughly a sixfold higher risk of eventually needing another operation.¹³ Another put the hazard ratio at nearly five for even mild residual regurgitation.³ This is why surgeons will sometimes convert to valve replacement on the spot if the intraoperative echo shows a less-than-ideal repair result.

Other preoperative predictors of reduced durability include elevated pulmonary artery pressure, a higher-than-normal pressure gradient across the valve, and weakened heart muscle function.¹³ Preoperative atrial fibrillation is another independent risk factor.⁹ When repairs do fail years later, the most common structural culprit is progressive leaflet thickening and stiffening, reflecting the fact that surgery can fix the mechanical problem but cannot stop the underlying degenerative process from marching forward. Other causes include new leaflet prolapse and occasionally the ring or sutures pulling free from the tissue.⁹

This last point deserves emphasis: even among patients who never need a second operation, roughly a third develop at least moderate recurrent leakage over 15 to 20 years.² Many of these people remain asymptomatic and are simply monitored. The repair has not “failed” in a clinical sense, but the valve is no longer perfect. Regular echocardiographic follow-up, typically every one to two years, is standard practice to catch progression before it causes symptoms or heart damage.¹⁴

Your Surgeon’s Volume Matters More Than You Might Think

One of the strongest and most consistent findings in mitral valve surgery research is the volume-outcome relationship. Surgeons and hospitals that perform more mitral operations get better results. A national study found that for every additional 10 mitral operations a surgeon performed annually, the odds of choosing repair over replacement increased, the risk of reoperation dropped, and one-year survival improved.¹⁵ The reoperation risk continued to decrease steadily until about 25 total mitral operations per year, at which point the curve flattened out. A separate analysis of U.S. data confirmed that increasing hospital and surgeon volumes were linked to lower mortality, fewer complications, and higher repair rates.¹⁶

The practical takeaway: if you are facing mitral valve surgery and have the option to travel to a high-volume center, the data strongly suggest it is worth doing. Even a modest difference in surgeon experience can translate into a meaningful difference in whether you get a repair at all, and how long that repair lasts.

Repair Versus Replacement

One of the first questions patients ask is whether they should push for a repair or accept a replacement with a mechanical or biological valve. Whenever a repair is technically feasible, it is generally preferred, and the survival numbers illustrate why. A large study of Medicare beneficiaries found that 10-year survival was about 54% after repair compared with 37% after replacement, with substantially lower operative mortality for repair.¹⁷ Some of that survival gap reflects patient selection: sicker patients are more likely to receive a replacement because their valves are harder to repair. But even after accounting for that, repair consistently comes out ahead in most analyses.

Repair also avoids permanent blood-thinner therapy, which is required with mechanical replacement valves. After a mitral repair, anticoagulation is typically temporary. One study found that a short course of warfarin after repair was associated with fewer combined bleeding and clotting complications, though the authors noted that anticoagulation adds logistical burden and lifestyle restrictions.¹⁸ A systematic review raised questions about how much benefit these blood thinners provide in the long run after repair, suggesting the picture is not entirely settled.¹⁹

Transcatheter Repair Is Less Durable but Has Its Place

Over the past decade, transcatheter edge-to-edge repair (commonly known by the brand name MitraClip) has emerged as an alternative for patients who are too frail or sick for open surgery. The device clips the two valve leaflets together through a catheter threaded up from the groin, creating a double-opening valve that leaks less. Recovery is faster and there is no chest incision, but the repair does not last as long.

An expert overview pooling data from multiple studies found that recurrence of significant leakage after transcatheter repair increased from around 5–10% in the first few months to about 17% at five years, with reintervention rates reaching about 9%.²⁰ Patients with degenerative (primary) mitral regurgitation fared worse, with about 41% experiencing recurrence or reintervention at five years.²⁰

Head-to-head comparisons with surgical repair make the gap vivid. In matched groups of patients with posterior leaflet prolapse, the prevalence of at least moderate leakage at three years was 43% after the clip versus about 3% after surgery.²¹ Among octogenarians, who might seem like ideal candidates for the less invasive approach, a comparative study found that recurrent leakage was still far more common after the clip (about 33%) than after surgery (about 6%), and five-year survival actually favored surgery.²² These findings have reinforced the view that transcatheter repair is best reserved for patients who truly cannot tolerate open surgery, rather than as a convenience alternative for those who could safely have the conventional operation.

When a Repair Fails, What Happens Next

A failed mitral repair does not mean disaster. If the valve starts leaking significantly again years down the road, reoperation is generally safe and effective. In one series, no in-hospital deaths occurred among patients who underwent re-repair, and freedom from severe leakage after a second repair was 93% at seven years.²³ A meta-analysis confirmed that re-repair, when technically possible, was associated with better outcomes than converting to a replacement valve.²⁴

For patients who are not good candidates for another open-heart surgery, transcatheter valve-in-ring implantation offers a newer option. This involves placing a bioprosthetic valve inside the previously implanted annuloplasty ring via catheter. Results from a large registry found a four-year survival rate of about 50% for valve-in-ring patients, with significant residual leakage more common than with valve-in-valve implantation for failed bioprosthetic replacements.²⁵ Residual leakage after these transcatheter redo procedures was independently associated with worse survival, so the technology works but is imperfect. It remains a reasonable bailout option for patients who cannot undergo another conventional operation.

Repair Durability in Children

Mitral valve repair in children deserves its own discussion because growing hearts add a dimension of complexity that adults never face. One study found that 10-year freedom from reoperation in children was about 85%, which sounds strong until you consider that children have many more decades of life ahead of them than the typical adult surgical patient.²⁶ A more detailed analysis of 112 children found that the cumulative incidence of reintervention climbed to about 33% at 10 years and 47% at 20 years.²⁷ The key predictor of reintervention in children was not residual leakage, as it is in adults, but rather a higher pressure gradient across the valve after surgery, suggesting that overly aggressive repairs that narrow the valve opening may fail sooner.²⁸ Many pediatric patients will need at least one additional operation during their lifetime, but repair is still strongly preferred over replacement in children because it preserves heart growth potential and avoids lifelong anticoagulation.

Connective Tissue Disorders and Emerging Frontiers

Patients with connective tissue disorders like Marfan syndrome and Ehlers-Danlos syndrome have long been assumed to have worse repair durability because their tissue is inherently weaker. The evidence so far, however, is cautiously reassuring. One study of adults with connective tissue disease found that none required reintervention or had significant recurrent leakage at a median follow-up of about three and a half years.²⁹ The follow-up is still relatively short by valve surgery standards, so the jury remains out on truly long-term outcomes, but early results suggest that modern repair techniques hold up even in tissue that might seem less forgiving.

Meanwhile, research into computational modeling is beginning to change how surgeons plan repairs. Researchers have developed frameworks that combine three-dimensional imaging of a patient’s valve with computer simulations of how different repair strategies would perform under the mechanical stresses of a beating heart.³⁰ These tools can estimate the stress distribution across the leaflets after a proposed repair, potentially helping surgeons choose techniques that minimize future stress on the tissue.³¹ The technology is not yet part of routine clinical practice, but it represents the direction the field is heading: using patient-specific simulations to choose the repair approach most likely to last a lifetime.